Complete Aims for Clinical Market as it Readies its WG Haplotyping Tech for Launch | GenomeWeb

This article was originally published July 12.

Complete Genomics is planning to introduce technology next year that will enable whole genome sequencing and haplotyping with an error rate as low as one in 10 million.

The company published a paper in Nature last week detailing its long-fragment read technology, which Complete Genomics CEO Cliff Reid said would truly enable clinical grade genomes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.